ArticleThe Pan African medical journal2025
Incidental prostate cancer status in two tertiary centers in Kigali, Rwanda: insights from a retrospective review.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: prostate cancer is reported in 16.7% of benign prostate hyperplasia (BPH) surgical specimens. This incidental prostate cancer (IPCa) is usually low grade. While incidence rates vary widely across regions, no published data exist from Rwanda, thus motivating this study. Methods: this was a retrospective cross-sectional analysis of Trans-Urethral Resection of Prostate (TURP) and open simple prostatectomy specimens from two tertiary hospitals between January 2015 and October 2022 to identify IPCa rate. The clinical characteristics and pathology reports were retrieved. Independent t-test, Fisher´s exact test, and logistic regression were performed to assess associations between clinical characteristics and occurrence of IPCa. Results: we included 153 patients, mean age 70 years (SD: ±10). 140/153 patients had Lower Urinary Tract Symptoms (LUTS), macrohematuria 4/153, and low back pain 1/153. IPCa was diagnosed in six individuals (6/153, 4%). One patient (1/6) with hematuria and the sole patient with low back pain had IPCa diagnosis (respectively OR: 16.4, 95% CI: 1.1 - 235.9, P=0.04 and OR 38.8, 95% CI: 1.5 - 881.2, P=0.02). Age, prostate volume, and a PSA >4ng/mL were not predictors of IPCa. Grade group (GG) 2 had 2/6 patients, while GG 1, 3, 4, and 5 had 1/6 each. Clinically, 1/6 were cT1a, 5/6 cT1b, with one patient upstaged to T3b postoperatively. Cancer management was watchful waiting in 2/6, active surveillance in 1/6, and androgen deprivation therapy in 3/6 patients. Conclusion: the incidence of prostate cancer in BPH specimens may be low but occasionally high-grade. Patients with symptoms beyond LUTS need careful assessment preoperatively. Larger prospective studies are needed to corroborate these findings for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.